טוען...
Brentuximab vedotin as monotherapy for unresectable breast implant‐associated anaplastic large cell lymphoma
BI‐ALCL is a rare CD30+ T‐cell malignancy, which is known to complicate textured breast implants. The CD30‐targeting immunoconjugate, brentuximab vedotin, has been suggested for invasive BI‐ALCL; however, its efficacy for unresectable BI‐ALCL has not been demonstrated. We present a case of unresecta...
שמור ב:
| הוצא לאור ב: | Clin Case Rep |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6510013/ https://ncbi.nlm.nih.gov/pubmed/31110735 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.2142 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|